NCT06761651View on ClinicalTrials.gov

A Study of TAVO412 in Patients with Cancer (TAVO412)

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

October 15, 2026

Conditions
Cancer
Interventions
DRUG

TAVO412

Biologic

Trial Locations (6)

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

Unknown

NOT_YET_RECRUITING

Affiliated Cancer Hospital of Chongqing University, Chongqing

NOT_YET_RECRUITING

First Affiliated Hospital of Xiamen University, Xiamen

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

RECRUITING

Hubei Cancer Hospital, Wuhan

RECRUITING

Jinan Central Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Tavotek Biotherapeutics

INDUSTRY

NCT06761651 - A Study of TAVO412 in Patients with Cancer (TAVO412) | Biotech Hunter | Biotech Hunter